Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab plus tyrosine kinase inhibitor with modified BFM chemotherapy for newly diagnosed Ph+ or ABL-class Ph-like B-ALL
NL-OMON59089Phase 3Not yet recruiting
- Sponsor
- University of Milano-Bicocca
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of blinatumomab, dasatinib and imatinib in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Milano-Bicocca. Primary endpoints: 3-year event-free survival in Ph+ B-ALL, 3-year event-free survival in ABL-class Ph-like B-ALL and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON59089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59089.